19 December 2018 - The agenda for the March 2019 PBAC meeting is now available.

The PBAC will consider 58 (29 major, 29 minor) at its next scheduled meeting in March 2019.

The Committee will consider two reports from the Drug Utilisation Subcommittee for medicines for:

• Non-Hodgkin’s lymphoma (1 medicine)
  
• Haemolytic uraemic syndrome (1 medicine)
  

The PBAC will also consider matters relating to the post-market review of medicines for pulmonary arterial hypertension (8 medicines).

9 (16%) of the 58 submissions are for a new medicine.

18 (31%) of the 58 submissions are resubmissions; most are for a new medicine or a new indication.

Just under a third of all submissions are for oncology medicines.

Roche is the leading applicant (6 submissions, 3 major).

Insights

• The PBAC will consider two submissions for a new biosimilar medicine (trastuzumab)
  
• The PBAC will consider resubmissions for two medicines rejected many years ago; bevacizumab (Avastin) for brain cancer (rejected in 2010) and darbepoetin alfa (Aranesp) for chemotherapy-induced neutropenia (last rejected in 2008).
  
• The PBAC will consider first ever submissions from Indivior and iCare Pharma Distributors
  
• Boehringer Ingelheim has lodged a minor submission requesting that Spiriva not be ‘a’ flagged with Teva Pharmaceuticals’ Braltas.
  

Read agenda for 2019/1 PBAC meeting

Read summary